Literature DB >> 28992280

Plasma biomarkers improve prediction of diabetic kidney disease in adults with type 1 diabetes over a 12-year follow-up: CACTI study.

Petter Bjornstad1,2, Laura Pyle1, David Z I Cherney3, Richard J Johnson4, Rachel Sippl2, Randy Wong2, Marian Rewers1,2, Janet K Snell-Bergeon1,2.   

Abstract

Background: The objective of the study was to determine whether plasma biomarkers of kidney injury improve the prediction of diabetic kidney disease (DKD) in adults with type 1 diabetes (T1D) over a period of 12 years.
Methods: Participants (n = 527, 53% females) in the Coronary Artery Calcification in T1D (CACTI) Study were examined during 2002-04, at a mean (± standard deviation) age of 39.6 ± 9.0 years with 24.8 years as the median duration of diabetes. Urine albumin-to-creatinine (ACR) and estimated glomerular filtration rate (eGFR) by CKD-EPI (chronic kidney disease epidemiology collaboration) creatinine were measured at the baseline and after mean follow-up of 12.1 ± 1.5 years. Albuminuria was defined as ACR ≥30 mg/g and impaired GFR as eGFR <60 mL/min/1.73 m2. Kidney injury biomarkers (Meso Scale Diagnostics) were measured on stored baseline plasma samples. A principal component analysis (PCA) identified two components: (i) kidney injury molecule-1, calbindin, osteoactivin, trefoil factor 3 and vascular endothelial growth factor; and (ii) β-2 microglobulin, cystatin C, neutrophil gelatinase-associated lipocalin and osteopontin that were used in the multivariable regression analyses.
Results: Component 2 of the PCA was associated with increase in log modulus ACR [β ± standard error (SE): 0.16 ± 0.07, P = 0.02] and eGFR (β ± SE: -2.56 ± 0.97, P = 0.009) over a period of 12 years after adjusting for traditional risk factors (age, sex, HbA1c, low-density lipoprotein cholesterol and systolic blood pressure and baseline eGFR/baseline ACR). Only Component 2 of the PCA was associated with incident-impaired GFR (odds ratio 2.08, 95% confidence interval 1.18-3.67, P = 0.01), adjusting for traditional risk factors. The addition of Component 2 to traditional risk factors significantly improved C-statistics and net-reclassification improvement for incident-impaired GFR (ΔAUC: 0.02 ± 0.01, P = 0.049, and 29% non-events correctly reclassified, P < 0.0001). Conclusions: Plasma kidney injury biomarkers can help predict development of DKD in T1D.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28992280      PMCID: PMC6030887          DOI: 10.1093/ndt/gfx255

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  35 in total

Review 1.  Uromodulin in kidney injury: an instigator, bystander, or protector?

Authors:  Tarek M El-Achkar; Xue-Ru Wu
Journal:  Am J Kidney Dis       Date:  2012-01-23       Impact factor: 8.860

Review 2.  Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis.

Authors:  Hans-Joachim Anders; Liliana Schaefer
Journal:  J Am Soc Nephrol       Date:  2014-04-24       Impact factor: 10.121

3.  Interpreting incremental value of markers added to risk prediction models.

Authors:  Michael J Pencina; Ralph B D'Agostino; Karol M Pencina; A Cecile J W Janssens; Philip Greenland
Journal:  Am J Epidemiol       Date:  2012-08-08       Impact factor: 4.897

4.  Uromodulin triggers IL-1β-dependent innate immunity via the NLRP3 inflammasome.

Authors:  Murthy Narayana Darisipudi; Dana Thomasova; Shrikant R Mulay; Dorothee Brech; Elfriede Noessner; Helen Liapis; Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2012-09-20       Impact factor: 10.121

5.  Evaluation of neutrophil gelatinase-associated lipocalin in normoalbuminuric normotensive type 1 diabetic adolescents.

Authors:  Korcan Demir; Ayhan Abaci; Tuncay Küme; Ayça Altincik; Gönül Catli; Ece Böber
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

Review 6.  Statistical methods for assessment of added usefulness of new biomarkers.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Clin Chem Lab Med       Date:  2010-08-18       Impact factor: 3.694

7.  In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study.

Authors:  T J Orchard; A M Secrest; R G Miller; T Costacou
Journal:  Diabetologia       Date:  2010-07-28       Impact factor: 10.122

8.  Shedding of the urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by MAP kinases and juxtamembrane region.

Authors:  Zhiwei Zhang; Benjamin D Humphreys; Joseph V Bonventre
Journal:  J Am Soc Nephrol       Date:  2007-10       Impact factor: 10.121

9.  Involvement of neutrophil gelatinase-associated lipocalin and osteopontin in renal tubular regeneration and interstitial fibrosis after cisplatin-induced renal failure.

Authors:  Emi Kashiwagi; Yutaka Tonomura; Chiaki Kondo; Koichi Masuno; Kae Fujisawa; Noriko Tsuchiya; Shuuichi Matsushima; Mikinori Torii; Nobuo Takasu; Takeshi Izawa; Mitsuru Kuwamura; Jyoji Yamate
Journal:  Exp Toxicol Pathol       Date:  2014-06-07

10.  Circulating serum trefoil factor 3 (TFF3) is dramatically increased in chronic kidney disease.

Authors:  Ting-yi Du; Hui-ming Luo; Hai-chun Qin; Fang Wang; Qing Wang; Yang Xiang; Yun Zhang
Journal:  PLoS One       Date:  2013-11-25       Impact factor: 3.240

View more
  9 in total

1.  Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes.

Authors:  Andreas Heinzel; Michael Kammer; Gert Mayer; Roman Reindl-Schwaighofer; Karin Hu; Paul Perco; Susanne Eder; Laszlo Rosivall; Patrick B Mark; Wenjun Ju; Matthias Kretzler; Peter Gilmour; Jonathan M Wilson; Kevin L Duffin; Moustafa Abdalla; Mark I McCarthy; Georg Heinze; Hiddo L Heerspink; Andrzej Wiecek; Maria F Gomez; Rainer Oberbauer
Journal:  Diabetes Care       Date:  2018-07-06       Impact factor: 19.112

2.  A Targeted Multiomics Approach to Identify Biomarkers Associated with Rapid eGFR Decline in Type 1 Diabetes.

Authors:  Christine P Limonte; Erkka Valo; Daniel Montemayor; Farsad Afshinnia; Tarunveer S Ahluwalia; Tina Costacou; Manjula Darshi; Carol Forsblom; Andrew N Hoofnagle; Per-Henrik Groop; Rachel G Miller; Trevor J Orchard; Subramaniam Pennathur; Peter Rossing; Niina Sandholm; Janet K Snell-Bergeon; Hongping Ye; Jing Zhang; Loki Natarajan; Ian H de Boer; Kumar Sharma
Journal:  Am J Nephrol       Date:  2020-10-14       Impact factor: 3.754

3.  The Next Frontier: Biomarkers and Artificial Intelligence Predicting Cardiorenal Outcomes in Diabetic Kidney Disease.

Authors:  Gregory L Braden; Daniel L Landry
Journal:  Kidney360       Date:  2022-09-29

4.  Association of Systemic Inflammatory Factors with Progression to Advanced Age-related Macular Degeneration.

Authors:  Brandie D Wagner; Jennifer L Patnaik; Alan G Palestine; Ashley A Frazer-Abel; Rebecca Baldermann; V Michael Holers; Marc T Mathias; Naresh Mandava; Anne M Lynch
Journal:  Ophthalmic Epidemiol       Date:  2021-04-08

Review 5.  Biomarkers of diabetic kidney disease.

Authors:  Helen M Colhoun; M Loredana Marcovecchio
Journal:  Diabetologia       Date:  2018-03-08       Impact factor: 10.122

6.  Plasma Metabolome and Lipidome Associations with Type 2 Diabetes and Diabetic Nephropathy.

Authors:  Yan Ming Tan; Yan Gao; Guoshou Teo; Hiromi W L Koh; E Shyong Tai; Chin Meng Khoo; Kwok Pui Choi; Lei Zhou; Hyungwon Choi
Journal:  Metabolites       Date:  2021-04-08

7.  REG1A and RUNX3 Are Potential Biomarkers for Predicting the Risk of Diabetic Kidney Disease.

Authors:  Xinyu Wang; Han Wu; Guangyan Yang; Jiaqing Xiang; Lijiao Xiong; Li Zhao; Tingfeng Liao; Xinyue Zhao; Lin Kang; Shu Yang; Zhen Liang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-22       Impact factor: 6.055

Review 8.  Review of potential biomarkers of inflammation and kidney injury in diabetic kidney disease.

Authors:  Vuthi Khanijou; Neda Zafari; Melinda T Coughlan; Richard J MacIsaac; Elif I Ekinci
Journal:  Diabetes Metab Res Rev       Date:  2022-07-11       Impact factor: 8.128

Review 9.  Protective factors as biomarkers and targets for prevention and treatment of diabetic nephropathy: From current human evidence to future possibilities.

Authors:  Natalia Nowak
Journal:  J Diabetes Investig       Date:  2020-05-06       Impact factor: 4.232

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.